Published in Women's Health Weekly, January 11th, 2001
The data were presented by Drs. Li Liu and W. Joseph Thompson from Cell Pathways and their collaborators, Drs. Mark Pegram and Dennis Slamon at the University of California, Los Angeles, Jonsson Cancer Center
The researchers also reported that in breast cancer lines that overexpress HER-2/neu or estrogen receptors, exisulind and CP461 each demonstrate synergistic anticancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.